Cargando…
Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis
The assurance of safety and effectiveness is a significant focal point in all therapeutic approaches. Although mesenchymal stem cells (MSCs) have been identified as a potential novel therapeutic strategy for multiple sclerosis (MS), existing evidence regarding the effectiveness and safety of this st...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573670/ https://www.ncbi.nlm.nih.gov/pubmed/37834955 http://dx.doi.org/10.3390/jcm12196311 |
_version_ | 1785120518288965632 |
---|---|
author | Islam, Md Asiful Alam, Sayeda Sadia Kundu, Shoumik Ahmed, Saleh Sultana, Shabiha Patar, Azim Hossan, Tareq |
author_facet | Islam, Md Asiful Alam, Sayeda Sadia Kundu, Shoumik Ahmed, Saleh Sultana, Shabiha Patar, Azim Hossan, Tareq |
author_sort | Islam, Md Asiful |
collection | PubMed |
description | The assurance of safety and effectiveness is a significant focal point in all therapeutic approaches. Although mesenchymal stem cells (MSCs) have been identified as a potential novel therapeutic strategy for multiple sclerosis (MS), existing evidence regarding the effectiveness and safety of this strategy remains inconclusive. Thus, the primary aim of this systematic review and meta-analysis (SRMA) was to comprehensively assess the effectiveness and safety of MSC therapy in individuals diagnosed with MS. A comprehensive search was conducted using appropriate keywords in the PubMed, Scopus, Cochrane, ScienceDirect, and Google Scholar databases to determine the eligible studies. The change in the expanded disability status scale (EDSS) score from baseline to follow-up was used to assess MSC efficacy. The effectiveness of the therapy was assessed using a random-effects model, which calculated the combined prevalence and 95% confidence intervals (CIs) for MS patients who experienced improvement, stability, or worsening of their condition. The protocol was registered in PROSPERO (CRD42020209671). The findings indicate that 40.4% (95% CI: 30.6–50.2) of MS patients exhibited improvements following MSC therapy, 32.8% (95% CI: 25.5–40.1) remained stable, and 18.1% (95% CI: 12.0–24.2) experienced a worsening of their condition. Although no major complications were observed, headaches 57.6 [37.9–77.3] and fever 53.1 [20.7–85.4] were commonly reported as minor adverse events. All of the results reported in this meta-analysis are consistent and credible according to the sensitivity analyses. Regardless of different individual studies, our meta-analysis provides a comprehensive overview showing the potential of MSC therapy as a possible effective treatment strategy for patients with MS. |
format | Online Article Text |
id | pubmed-10573670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105736702023-10-14 Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis Islam, Md Asiful Alam, Sayeda Sadia Kundu, Shoumik Ahmed, Saleh Sultana, Shabiha Patar, Azim Hossan, Tareq J Clin Med Systematic Review The assurance of safety and effectiveness is a significant focal point in all therapeutic approaches. Although mesenchymal stem cells (MSCs) have been identified as a potential novel therapeutic strategy for multiple sclerosis (MS), existing evidence regarding the effectiveness and safety of this strategy remains inconclusive. Thus, the primary aim of this systematic review and meta-analysis (SRMA) was to comprehensively assess the effectiveness and safety of MSC therapy in individuals diagnosed with MS. A comprehensive search was conducted using appropriate keywords in the PubMed, Scopus, Cochrane, ScienceDirect, and Google Scholar databases to determine the eligible studies. The change in the expanded disability status scale (EDSS) score from baseline to follow-up was used to assess MSC efficacy. The effectiveness of the therapy was assessed using a random-effects model, which calculated the combined prevalence and 95% confidence intervals (CIs) for MS patients who experienced improvement, stability, or worsening of their condition. The protocol was registered in PROSPERO (CRD42020209671). The findings indicate that 40.4% (95% CI: 30.6–50.2) of MS patients exhibited improvements following MSC therapy, 32.8% (95% CI: 25.5–40.1) remained stable, and 18.1% (95% CI: 12.0–24.2) experienced a worsening of their condition. Although no major complications were observed, headaches 57.6 [37.9–77.3] and fever 53.1 [20.7–85.4] were commonly reported as minor adverse events. All of the results reported in this meta-analysis are consistent and credible according to the sensitivity analyses. Regardless of different individual studies, our meta-analysis provides a comprehensive overview showing the potential of MSC therapy as a possible effective treatment strategy for patients with MS. MDPI 2023-09-30 /pmc/articles/PMC10573670/ /pubmed/37834955 http://dx.doi.org/10.3390/jcm12196311 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Islam, Md Asiful Alam, Sayeda Sadia Kundu, Shoumik Ahmed, Saleh Sultana, Shabiha Patar, Azim Hossan, Tareq Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis |
title | Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis |
title_full | Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis |
title_fullStr | Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis |
title_short | Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis |
title_sort | mesenchymal stem cell therapy in multiple sclerosis: a systematic review and meta-analysis |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573670/ https://www.ncbi.nlm.nih.gov/pubmed/37834955 http://dx.doi.org/10.3390/jcm12196311 |
work_keys_str_mv | AT islammdasiful mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis AT alamsayedasadia mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis AT kundushoumik mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis AT ahmedsaleh mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis AT sultanashabiha mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis AT patarazim mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis AT hossantareq mesenchymalstemcelltherapyinmultiplesclerosisasystematicreviewandmetaanalysis |